Cofrogliptin clinical trials
How each study uses cofrogliptin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the cofrogliptin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Cofrogliptin
- 2
Studies by the year they started
3 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
Second Xiangya Hospital of Central South University (1) · Haisco Pharmaceutical Group Co., Ltd. (1) · Huazhong University of Science and Technology (1)
Related medicines
As reviewed, each with the page that says it.
- One of DPP-4 inhibitors source
- One of Protease Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test cofrogliptin.
- Jun 2027A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Naïve Patients With Type 2 DiabetesNot applicable · Haisco Pharmaceutical Group Co., Ltd.
Studies
Open first, then newest update. How each study uses cofrogliptin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Effects of Cofrogliptin on Beta-Cell Function in LADA PatientsNot yet recruitingNot applicableSecond Xiangya Hospital of Central South UniversityNCT07460336Written as Cofrogliptin
- A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Naïve Patients With Type 2 DiabetesNot yet recruitingNot applicableHaisco Pharmaceutical Group Co., Ltd.NCT07122102Written as Cofrogliptin
- Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.RecruitingPhase 4Huazhong University of Science and TechnologyNCT07019012Written as SGLT2i+Metformin+Cofrogliptin
As the comparator · 1 — what is tested is compared with cofrogliptin
Codes
What other systems call cofrogliptin · ClinicalTrials.gg INT017183
- UNII (FDA) LH4G6K6NKPCOFROGLIPTINConfirmed FDA, Wikidata
- Wikidata Q123846319cofrogliptinConfirmed FDA, Wikidata
- NCI Thesaurus C190467CofrogliptinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | LH4G6K6NKP | COFROGLIPTIN | Confirmed FDA, Wikidata |
| Wikidata | Q123846319 | cofrogliptin | Confirmed FDA, Wikidata |
| NCI Thesaurus | C190467 | Cofrogliptin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.